(NASDAQ: RANI) Rani Therapeutics Holdings's forecast annual revenue growth rate of 299.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Rani Therapeutics Holdings's revenue in 2025 is $1,200,000.On average, 2 Wall Street analysts forecast RANI's revenue for 2025 to be $9,782,158, with the lowest RANI revenue forecast at $9,782,158, and the highest RANI revenue forecast at $9,782,158. On average, 2 Wall Street analysts forecast RANI's revenue for 2028 to be $1,398,848,573, with the lowest RANI revenue forecast at $815,371,628, and the highest RANI revenue forecast at $1,982,325,517.
In 2029, RANI is forecast to generate $4,111,383,402 in revenue, with the lowest revenue forecast at $4,111,383,402 and the highest revenue forecast at $4,111,383,402.